Autopsy report · NCT06856681

Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease

“sponsor decision to cancel project before enrollment.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

C2N Diagnostics

Sponsor type

Industry

Conditions

Alzheimers Disease

Interventions

PrecivityAD2 - Early Testing; PrecivityAD2 - Delayed Testing

Participants

0

Trials that died the same way

• Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
  “Sponsor decision to terminate the program” (78% match in meaning)
• A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer
  “Sponsor decision to early terminate the study” (78% match in meaning)
• Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
  “Sponsor decision to terminate the study” (78% match in meaning)
• Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated
  “Sponsor decision to terminate study.” (77% match in meaning)
• Safety and Efficacy of Medical Cannabis Oil in the Treatment of Patients with Chronic Pain
  “Sponsor decision to stop the study” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.